The companies developing new weight-loss medicines have a problem: the balance of power has shifted, and patients are bailing ...

Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and ...

By Christy Santhosh March 19 (Reuters) - Eli Lilly's next-generation obesity drug showed a significant reduction in blood ...

The GLP-1 PR has been a little too good. Everyone knows the drugs lead to rapid weight loss — including participants in ...

Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to ...

Regeneron’s Chinese partner reported Zepbound-like efficacy in a phase 3 trial, de-risking one part of the Big Biotech’s differentiated play for the obesity market.

The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.

GIP obesity drug enters Phase 3 with strong cash runway, but rising competition and trial risk. Click for this VKTX update.

Rhythm Pharmaceuticals is switching up the tempo for its melanocortin-4 receptor (MC4R) agonist Imcivree. | The new FDA nod ...

The FDA has approved a higher 7.2 mg dose of Novo Nordisk’s Wegovy (Wegovy HD) for chronic weight management in adults with ...

Patients with obesity sometimes have leptin resistance, and the "full" feeling does not get through to the brain. The new ...

Chugai Pharmaceutical Co. fell 7.3%, the largest intraday decline since August 2025, after the company said it had ended the ...